Shares of Amgen Inc. AMGN rallied 1.13% to $290.33 Friday, on what proved to be an all-around great trading session for the ...

Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Novartis and Amgen also boast impeccable dividend track records, which should please investors. When broader equities are ...

The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

The guideline recommendations advise universal use of hydroxychloroquine, minimizing steroids, and earlier introduction of ...

Amgen (NasdaqGS:AMGN) recently announced interim results from its Phase 3 DeLLphi-304 trial for IMDELLTRA, showing ...

Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease ...

Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m. PT on Tuesday, June 10, 2025. Peter Griffith, executive vice president and chief financial ...

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.

Patent claims reciting compounds where at least one group of a compound genus is defined by its function are common. For ...